Orlando, FL -- (SBWIRE) -- 09/10/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY), Adept Technology Inc (NASDAQ:ADEP).
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) stock gained 12.83% to $2.99. The company on Sept. 9 announced final tumour response data from its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021). The analysis examined percent best overall tumour responses between pre-treatment and up to six treatment cycles. Of 25 evaluable patients who had more than one cycle of therapy, 23 (92%) exhibited overall tumour shrinkage (mean shrinkage was 32.7%).
Additionally, the company on August 1 announced its financial results and operational highlights for the quarter ended June 30, 2013 . The company exited the second quarter with over $36.1 million of cash, cash equivalents and short-term investments.
Are investors worried about the recent updates with ONCY? Find out with a free trend analysis HERE
Adept Technology Inc (NASDAQ:ADEP) shares increased 24.68% and closed at $5.86 in yesterday’s session. The company on Sept. 9 announced that it will host its North American Summit 2013 event in Pleasanton, CAOctober 15 - 17, 2013. The automation conference will feature industry leaders, real-world case studies, live automation demonstrations and a chance to network with automation leaders.
Additionally, the company on August 27 announced financial results for its fiscal 2013 fourth quarter and year-end (ended June 30, 2013). Revenues for the fourth quarter of fiscal 2013 were $13.7 million, compared with $10.9 million reported in the 2013 third quarter, and $17.0 million in the 2012 fourth quarter. The company reported GAAP net income of $157,000, or earnings of $0.00 per share on a diluted basis, in the 2013 fourth quarter. This compares with a net loss of $1.8 million, or a loss of $0.17 per share, in the 2013 third quarter, and a net loss of $358,000, or a loss of $0.04 per share in the 2012 fourth quarter.
Adept's non-GAAP adjusted EBITDA was $186,000 in the 2013 fourth quarter, compared with an adjusted EBITDA loss of $1.1 million in the 2013 third quarter, and an adjusted EBITDA loss of $341,000 in the 2012 fourth quarter.
Is ADEP going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)